OncoMatch/Clinical Trials/NCT07093814
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Is NCT07093814 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies VRT106 for glioblastoma.
Treatment: VRT106 — This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Prior therapy
Cannot have received: oncolytic virus
Previously received treatment with oncolytic viruses
Cannot have received: gene therapy
Previously received treatment with...gene therapy
Cannot have received: clinical investigational drug/device
Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07093814 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior oncolytic virus, gene therapy, clinical investigational drug/device disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages